# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001193125-26-032706
**Filing Date:** 2026-2
**Character Count:** 10797
**Document Hash:** 240076cf5561fa0d15db72e0b6d212b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-032706.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0001193125-26-032706

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 63

**CONFORMED PERIOD OF REPORT**: 20260202

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 26585774

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** February 02, 2026<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On February 2, 2026, Perspective Therapeutics, Inc. (the "Company") updated its corporate presentation (the "Presentation"). The Presentation contains certain estimated and projected financial information, including the Company's estimated cash, cash equivalents and short-term investments as of December 31, 2025. The estimated and projected financial information included in the Presentation is preliminary and has not been audited, reviewed or compiled by the Company's independent registered public accounting firm, WithumSmith+Brown, PC ("Withum"), and Withum has not performed any procedures with respect to the preliminary financial data. Accordingly, Withum does not express an opinion or any other form of assurance with respect thereto.

The Company's actual results as of December 31, 2025 may differ from the preliminary financial data due to the completion of the Company's closing procedures with respect to the year ended December 31, 2025, final adjustments and other developments that may arise between now and the time the financial results for the fiscal year are finalized.

## Item 8.01 Other Events.
On February 2, 2026, the Company posted the Presentation to its website. A copy of the Presentation is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Corporate Presentation</u>](catx-ex99_1.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | February 2, 2026 | By:  | /s/ Joel Sendek |
|  |  |  | Joel Sendek<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](catx-ex99_1s1.jpg)

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

------

![Slide 2](catx-ex99_1s2.jpg)

------

![Slide 3](catx-ex99_1s3.jpg)

Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology

------

![Slide 4](catx-ex99_1s4.jpg)

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

------

![Slide 5](catx-ex99_1s5.jpg)

Proprietary Radioligand Platform Optimizes Therapeutic Index

------

![Slide 6](catx-ex99_1s6.jpg)

Proprietary Pb-Based Chelator Designed for Broader and Safer Use

------

![Slide 7](catx-ex99_1s7.jpg)

Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters

------

![Slide 8](catx-ex99_1s8.jpg)

Imaging Optimizes Targeted Delivery to Tumor

------

![Slide 9](catx-ex99_1s9.jpg)

------

![Slide 10](catx-ex99_1s10.jpg)

Solid Tumors are an Attractive Market for Radiopharmaceuticals

------

![Slide 11](catx-ex99_1s11.jpg)

End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway

------

![Slide 12](catx-ex99_1s12.jpg)

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

------

![Slide 13](catx-ex99_1s13.jpg)

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

------

![Slide 14](catx-ex99_1s14.jpg)

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

------

![Slide 15](catx-ex99_1s15.jpg)

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

------

![Slide 16](catx-ex99_1s16.jpg)

Compelling Anti-tumor Activity with Sustained or Deepening Responses

------

![Slide 17](catx-ex99_1s17.jpg)

VMT-⍺-NET: Durable Disease Control Across All Doses

------

![Slide 18](catx-ex99_1s18.jpg)

Best-in-class Safety Profile1

------

![Slide 19](catx-ex99_1s19.jpg)

VMT-⍺-NET: Select Adverse Events of Special Interest

------

![Slide 20](catx-ex99_1s20.jpg)

VMT-α-NET's Compelling Profile Supports Potential Registration Study at Current Dose Level

------

![Slide 21](catx-ex99_1s21.jpg)

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

------

![Slide 22](catx-ex99_1s22.jpg)

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

------

![Slide 23](catx-ex99_1s23.jpg)

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

------

![Slide 24](catx-ex99_1s24.jpg)

Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

------

![Slide 25](catx-ex99_1s25.jpg)

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

------

![Slide 26](catx-ex99_1s26.jpg)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

------

![Slide 27](catx-ex99_1s27.jpg)

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

------

![Slide 28](catx-ex99_1s28.jpg)

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

------

![Slide 29](catx-ex99_1s29.jpg)

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

------

![Slide 30](catx-ex99_1s30.jpg)

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

------

![Slide 31](catx-ex99_1s31.jpg)

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

------

![Slide 32](catx-ex99_1s32.jpg)

------

![Slide 33](catx-ex99_1s33.jpg)

Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026

------

![Slide 34](catx-ex99_1s34.jpg)

------

![Slide 35](catx-ex99_1s35.jpg)

Abbreviations

------

![Slide 36](catx-ex99_1s36.jpg)

APPENDIX

------

![Slide 37](catx-ex99_1s37.jpg)

------

![Slide 38](catx-ex99_1s38.jpg)

NETs Trials

------

![Slide 39](catx-ex99_1s39.jpg)

VMT-⍺-NET: Baseline Patient Characteristics in ASCO-GI 2026 Data Analysis

------

![Slide 40](catx-ex99_1s40.jpg)

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO-GI 2026 Data Analysis

------

![Slide 41](catx-ex99_1s41.jpg)

VMT-⍺-NET: Durable Disease Control Across All Doses

------

![Slide 42](catx-ex99_1s42.jpg)

VMT-⍺-NET: Signal of Sustained Anti-tumor Activity

------

![Slide 43](catx-ex99_1s43.jpg)

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

------

![Slide 44](catx-ex99_1s44.jpg)

Blood Creatinine During Follow-up for All Patients Treated (n=56)

------

![Slide 45](catx-ex99_1s45.jpg)

Refractory Metastatic Melanoma Trials

------

![Slide 46](catx-ex99_1s46.jpg)

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

------

![Slide 47](catx-ex99_1s47.jpg)

------

![Slide 48](catx-ex99_1s48.jpg)

------

![Slide 49](catx-ex99_1s49.jpg)

Perspective's proprietary chelator has been optimized for lead-based RPTs

------

![Slide 50](catx-ex99_1s50.jpg)

------

![Slide 51](catx-ex99_1s51.jpg)

------

![Slide 52](catx-ex99_1s52.jpg)